Stock Market

SLS Stock Soars More Than 200% After Phase 3 Cancer Vaccine Success: What’s Next for SELLAS Life Sciences?

Published by
Shubham Vishwakarma

SLS stock has skyrocketed more than 200%, putting SELLAS Life Sciences among the market’s biggest gainers after a major breakthrough in its Phase 3 cancer vaccine trial. The sharp rally followed results showing a 41% reduction in the risk of death among patients with acute myeloid leukemia, giving the company a potentially significant path toward regulatory approval. 

With the announcement triggering an extraordinary repricing of the stock, investors are now watching how much further the rally can run.

SELLAS Cancer Vaccine Delivers Positive Phase 3 Results

The rally follows positive topline results from SELLAS Life Sciences’ pivotal Phase 3 REGAL trial, which evaluated galinpepimut-S (GPS) as a maintenance treatment for patients with AML who had achieved a second or later remission but were unable to undergo a stem-cell transplant.

The trial met its primary endpoint of overall survival, with GPS demonstrating a 41% reduction in the risk of death compared with the best available treatment. Patients receiving the experimental vaccine recorded a median overall survival of 24 months, against 14.7 months in the control group.

The results showed a hazard ratio of 0.59 and a p-value of 0.035, indicating a statistically significant improvement in survival. The treatment was also generally well tolerated, with no new safety signals reported.

The outcome is particularly important because AML is an aggressive blood cancer, and patients whose disease returns after initial treatment can face limited therapeutic options. GPS is designed to train the immune system to recognize and attack leukemia cells expressing the WT1 protein.

FDA Discussions Put 2027 Approval Timeline in Focus

The positive trial outcome gives SELLAS a clearer regulatory path, but the next milestone will depend on discussions with the U.S. Food and Drug Administration. The company plans to meet with the FDA to discuss an accelerated filing strategy while advancing preparations for a Biologics License Application submission in the first half of 2027.

A potential filing would move GPS closer to the regulatory review process, although the treatment is not yet approved for commercial use. Investors will also be watching for additional trial analyses and regulatory guidance that could clarify the timeline toward a possible launch.

Beyond GPS, SELLAS is advancing SLS009, its investigational CDK9 inhibitor being studied in AML. The company had previously indicated that preliminary topline data from its Phase 2 program were expected in the fourth quarter of 2026, adding another potential catalyst to its pipeline.

SLS Stock Price Analysis: Can Shares Extend the Rally Above $25?

SLS stock has staged an exceptional breakout, rising from its previous close of $7.47 to trade above $20 during the November 17 session. The move has taken the stock well beyond its earlier trading range, marking an intraday high near $24.89.

The immediate technical test is the $24–$25 resistance zone. A sustained move above this area could strengthen the breakout and keep momentum traders interested. However, the steep price expansion also raises the risk of sharp intraday reversals as early buyers look to secure profits.

On the downside, $16.70 is an important near-term support level based on the latest candle. If selling pressure intensifies, the $10–$11 region becomes another area to monitor, where the chart shows a previous price structure and moving-average support.

What’s Next for SELLAS Life Sciences Stock?

The REGAL trial results have given SELLAS a major clinical catalyst and significantly changed the near-term investment narrative around the company. The focus now shifts to FDA discussions, the potential 2027 BLA submission and further progress across its pipeline.

The next move will depend on whether buyers can defend the breakout as the market begins pricing in the longer-term potential of GPS.

Shubham Vishwakarma

Shubham Vishwakarma is a crypto market analyst and technical content writer who covers price action, on-chain signals, and breaking blockchain news. He simplifies complex market data into sharp, easy-to-understand insights, helping readers stay ahead of trends in Bitcoin, altcoins, and DeFi. His writing combines technical precision with compelling market storytelling.

Recent Posts

Magnificent 7 US Stocks : Meta, Amazon and Nvidia Lead the Buy List

The Magnificent 7 US stocks are facing renewed selling pressure as investors reassess technology valuations…

November 17, 2026

Can XRP Price Recover $1 After Lagging Bitcoin All Year?

XRP has slipped below $1 and set a fresh cycle low, deepening a roughly 75%…

November 17, 2026

Nvidia Stock Earnings Today Without Jensen Huang

Nvidia releases third-quarter fiscal 2027 results after the US market close on Tuesday, at about…

November 17, 2026

Microsoft Buyout Offer Reaches 60,000 Employees In US, India, UK And Canada

Microsoft is offering voluntary buyouts to more than 60,000 employees across the US, Canada, India…

November 17, 2026

BREAKING: Jensen Huang Finally Reveals He Will Return As Nvidia CEO If Board Asks

Jensen Huang has said he would come back as Nvidia’s chief executive if the company’s…

November 17, 2026

Bitcoin Price Faces $62-$64K Test as On-Chain Activity Diverges

Bitcoin’s network just recorded a transaction milestone, but the numbers aren’t exactly screaming bullish. November…

November 17, 2026